

1 **Changes in the stool and oropharyngeal microbiome in obsessive-compulsive** 2 **disorder**

3 Laura Domènech PhD ^{1#}, Jesse Willis BSc ¹, Maria Alemany BSc ^{2,3}, Marta Morell ¹, Eva Real MD, PhD ^{2,3},
4 Geòrgia Escaramís PhD ^{1,4}, Sara Bertolín MD ³, Daniel Sánchez Chinchilla BSc¹, Susanna Balcells PhD ^{5,6,7},
5 Cinto Segalàs MD PhD ^{2,3}, Xavier Estivill MD PhD ⁸, Jose M Menchón MD PhD ^{2,3,9,10}, Toni Gabaldón PhD
6 ^{1,11,12}, Pino Alonso MD PhD* ^{3,9,10}, Raquel Rabionet PhD* ^{1,5,6,7}

7 ¹ Bioinformatics and Genomics Programme, Centre for Genomic Regulation (CRG), The Barcelona
8 Institute of Science and Technology (BIST), Barcelona, Spain

9 ² Institut d' Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain

10 ³ OCD Clinical and Research Unit, Psychiatry Department, Hospital Universitari de Bellvitge, Barcelona,
11 Spain

12 ⁴ CIBERESP (Centro de Investigación en red de Epidemiología y Salud Pública), Instituto de Salud Carlos
13 III, Spain

14 ⁵ Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain

15 ⁶ CIBERER (Centro de Investigación en red de Enfermedades Raras), Instituto de Salud Carlos III, Spain

16 ⁷ Dept. Genetics, Microbiology & Statistics, Institut de Biomedicina de la Universitat de Barcelona (IBUB),
17 Faculty of Biology, University of Barcelona, Barcelona, Spain

18 ⁸ Genetics and Genomics Program, Sidra Medical Center, Doha, Qatar

19 ⁹ Department of Clinical Sciences, Bellvitge Campus, University of Barcelona, Barcelona, Spain

20 ¹⁰ CIBERSAM (Centro de Investigación en Red de Salud Mental), Instituto de Salud Carlos III, Spain

21 ¹¹ Universitat Pompeu Fabra (UPF), Barcelona, Spain

22 ¹² Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain

23 # current address: Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine,
24 Massachusetts General Hospital, Boston, MA.

25 * indicates equal contribution

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Corresponding authors:

Raquel Rabionet: Dept. of Genetics, Microbiology and Statistics,
Faculty of Biology, University of Barcelona
Av. Diagonal 643
08028 Barcelona
Spain
Tel. +34 635 536 508 Email: kelly.rabionet@ub.edu

Pino Alonso: OCD Clinical and Research Unit, Department of Psychiatry,
Hospital de Bellvitge
c/Feixa Llarga s/n
Hospitalet de Llobregat
08907 Barcelona
Spain
Tel. +34 93 260 7659 Email: mpalonso@bellvitgehospital.cat

1 **ABSTRACT**

2 Although the etiology of obsessive-compulsive disorder (OCD) is largely unknown, it is accepted that
3 OCD is a complex disorder. There is a known bi-directional interaction between the gut microbiome and
4 brain activity. Several authors have reported associations between changes in gut microbiota and
5 neuropsychiatric disorders, including depression or autism. Furthermore, a pediatric-onset
6 neuropsychiatric OCD-related syndrome occurs after streptococcal infection, which might indicate that
7 exposure to certain microbes could be involved in OCD susceptibility. However, only one study has
8 investigated the microbiome of OCD patients to date. We performed 16S ribosomal RNA gene-based
9 metagenomic sequencing to analyze the stool and oropharyngeal microbiome composition of 32 OCD
10 cases and 32 age and gender matched controls. We estimated different α - and β -diversity measures and
11 performed LEfSe and Wilcoxon tests to assess differences in bacterial distribution. OCD stool samples
12 showed a trend towards lower bacterial α -diversity, as well as an increase of the relative abundance of
13 *Rikenellaceae*, particularly of the genus *Alistipes*, and lower relative abundance of *Prevotellaceae*, and
14 two genera within the *Lachnospiraceae*: *Agathobacter* and *Coprococcus*. However, we did not observe a
15 different Bacteroidetes to Firmicutes ratio between OCD cases and controls. Analysis of the
16 oropharyngeal microbiome composition showed a lower Fusobacteria to Actinobacteria ratio in OCD
17 cases. In conclusion, we observed an imbalance in the gut and oropharyngeal microbiomes of OCD
18 cases, including, in stool, an increase of bacteria from the *Rikenellaceae* family, associated with gut
19 inflammation, and a decrease of bacteria from the *Coprococcus* genus, associated with DOPAC synthesis.

20

21

22

23

1

2 INTRODUCTION

3 Obsessive-compulsive disorder (OCD) is a neuropsychiatric disorder characterized by intrusive and
4 unwanted thoughts (termed obsessions) and repetitive behaviors or mental acts (called compulsions)
5 that are performed to partially relieve the anxiety or distress caused by the obsessions. The etiology of
6 OCD is largely unknown, although it likely involves a combination of genetic, neurobiological and
7 environmental factors or events. Genetic association studies, including genome-wide association
8 analysis and a multispecies approach integrating evolutionary and regulatory information, have
9 highlighted genes involved in dopamine, serotonin and glutamate signaling, synaptic connectivity and
10 the cortico-striato-thalamo-cortical circuit (CSTC) (Gasso et al., 2015; Mattheisen et al., 2015; Noh et al.,
11 2017; Servaes et al., 2017; Stewart et al., 2013).

12 Several researchers have speculated that the microbiome might also play a role in the development of
13 OCD (Rees, 2014; Turna et al., 2016). In fact, a recent pilot study of the gut microbiome in OCD has
14 observed some dysbiosis in OCD cases compared to controls (Turna et al., 2020), and a previous work
15 observed a difference in gut microbial composition in deer mice presenting an obsessive behavior
16 compared to the normal individuals (Scheepers et al., 2019), while microbial treatments such as germ-
17 free environment and probiotic treatments can modify OCD-like behavior in rodents (Bastiaanssen et al.,
18 2019), and some OCD risk factors, such as stress, pregnancy or antibiotic use, are known to disrupt the
19 gut microbiome (Rees, 2014). Moreover, it is recognized that some children, after suffering a
20 streptococcal infection, present with a sudden onset of tics, OCD and other behavioral symptoms, a
21 condition known as pediatric autoimmune neuropsychiatric disorders associated with streptococcal
22 infections syndrome (PANS/PANDAS) (Snider and Swedo, 2004).

23 There is a well-known bi-directional interaction between the gut microbiota and brain activity (Cryan
24 and Dinan, 2012; Mayer et al., 2014). Brain function can be affected by endocrine-, neurocrine- and

1 inflammation-related signals from the gut microbiota, while psychological and physical stressors can
2 affect the composition of the gut microbiome (Bailey et al., 2011; Partrick et al., 2018). Differences in
3 the composition of the gut microbiome have been associated to depression (Valles-Colomer et al.,
4 2019), autistic disorder (Liu et al., 2019a; Tomova et al., 2015; Vuong and Hsiao, 2017), or schizophrenia
5 (Schwarz et al., 2018), among other psychiatric disorders. Moreover, two studies have found differences
6 in gut bacterial distribution when OCD cases or PANS/PANDAS patients are compared to healthy age-
7 matched individuals (Quagliariello et al., 2018; Turna et al., 2020). On the other hand, some studies have
8 also shown an alteration of the oropharyngeal microbiome in patients with autism (Hicks et al., 2018;
9 Qiao et al., 2018) or schizophrenia (Castro-Nallar et al., 2015). However, so far, only one study has
10 explored a potential link between gut microbiota and OCD, and the OCD oral microbiota has not been
11 explored yet. Here, we explore the composition of fecal and oropharyngeal microbiota of OCD-patients
12 before and after treatment and compare it to healthy matched controls.

13

14 **MATERIAL AND METHODS**

15 **Sample collection**

16 Thirty-eight patients (20 females; mean age=40.16±14.12, see Table 1) with a diagnosis of OCD with at
17 least one year of development were recruited from the OCD clinic at Bellvitge Hospital (Barcelona,
18 Spain) from January 2016 to September 2017. Diagnoses were assigned by two psychiatrists with
19 extensive clinical experience in OCD, following the DSM-IV criteria for OCD diagnosis (Association, 1994)
20 and using the Structured Clinical Interview for DSM-IV Axis I Disorders-Clinician Version (SCID-I) (First et
21 al., 1996). A summary of the patients' clinical data is provided in supplementary Table S1. Patients
22 presenting psychoactive substance abuse/dependence (current or in the past six months), psychotic
23 disorders, intellectual disability, severe organic or neurological pathology (excepting tic disorder), or

1 autism spectrum disorder were excluded from the study. Other affective and anxiety disorders were not
2 criteria for exclusion in cases where OCD was the main diagnosis.

3 Thirty-three healthy controls (18 females; mean age=36±9.87) were recruited from the same
4 sociodemographic environment and constituted a comparable sample in terms of age and gender (see
5 Table 1 and supplementary Table S2 for a summary of clinical information on controls). Prior to
6 inclusion, each control participant underwent the Structured Clinical Interview for DSM-IV non-patient
7 version (SCID-NP) (First et al., 2002) to exclude presence or history of any psychiatric disorder.

8 Written informed consent was obtained from all participants after a complete description of the study,
9 which was performed in accordance with the Declaration of Helsinki (2013) and approved by Bellvitge
10 Hospital's ethical committee.

11 Stool samples from 28 OCD cases at two time-points (before (OCD T0) and after (OCD T3) three months
12 of pharmacological treatment and cognitive behavioral therapy), 7 OCD cases at a single time-point (4
13 OCD T0 and 3 OCD T3), and 33 healthy subjects were collected in Stool Collection Tubes (Stratec
14 Molecular). Samples were stored at -20°C until processed. DNA was extracted using the PSP Spin Stool
15 DNA Basic Kit (Stratec Molecular).

16 Oropharyngeal swab samples, corresponding to the tonsils and the back of the throat, from 28 OCD
17 cases at two time-points, 8 single timepoint OCD cases (4 OCD T0 and 4 OCD T3) and 32 healthy
18 individuals were collected with the Catch-All sample collection swabs (Epicentre), conserved in
19 PowerBead tubes (MO BIO Laboratories), frozen at -20°C and processed for DNA extraction with the
20 PowerSoil DNA Isolation kit (MO BIO Laboratories). Details for the overlap between stool T0, stool T3,
21 oropharyngeal T0 and oropharyngeal T3 samples are provided in Figure S1.

22 Sample sizes were deemed appropriate for this exploratory approach considering previous similar
23 studies of microbiota involvement in other psychiatric disorders (Castro-Nallar et al., 2015; Qiao et al.,

1 2018; Quagliariello et al., 2018; Schwarz et al., 2018; Tomova et al., 2015; Turna et al., 2020), performed
2 with similar sample sizes.

3 All participants were asked to provide dietary information through a questionnaire (supplementary
4 tables S3 and S4). Severity of the obsessive and compulsive symptoms before and after treatment
5 among the OCD patients was assessed through the clinician-administered version of the Yale-Brown
6 Obsessive Compulsive Scale (Y-BOCS) (Goodman et al., 1989). A global measure as well as independent
7 ones for both obsessions and compulsions were taken. Table 1 and supplementary Tables S1 and S2
8 summarize the main characteristics of the OCD and control cohorts.

9 **Sequencing and data analysis**

10 16S ribosomal RNA (rRNA) sequencing was performed by the UPF Genomics Core Facility following
11 Illumina's protocol with slight modifications. Briefly, in each sample, the variable V3-V4 region of the 16S
12 rRNA gene was amplified for 35 cycles using the primers described in Klindworth et al. (Klindworth et al.,
13 2013) and Platinum High Fidelity Taq (Thermofisher) and purified, followed by 8 cycles of indexing PCR,
14 and quantification. The indexed products were then pooled in an equimolar way in two final amplicon
15 libraries (one for stool and one for tonsils), each containing 96 samples. Each library was sequenced in
16 one 2 x 300 bp paired-end sequencing run on a MiSeq System.

17 The DADA2 R package (version 1.6.0) (Callahan et al., 2016) was employed to obtain counts of amplicon
18 sequence variants (ASV), and sequence taxonomy was assigned using the SILVA database (Yilmaz et al.,
19 2014). Resulting ASV counts, along with clinical data and diet information collected for each individual,
20 were stored and analyzed using the Phyloseq package (version 1.22.3). 16S counts were normalized per
21 sample, obtaining the relative abundance of each taxon within a sample, with all values ranging
22 between 0 and 100.

23 We estimated different α - (within samples) and β -diversity (between samples) measures using the
24 Phyloseq, picante and vegan R packages (see supplementary material for details). α -diversity indices

1 included the Shannon and Simpson Diversity Index, Faith's phylogenetic diversity, the observed species
2 index, the Chao1 index and the ACE (Abundance-based Coverage Estimator) index. β -diversity measures
3 included Unifrac distances, the Bray-Curtis dissimilarity, Jensen-Shannon diversity and Canberra indices.
4 We performed a PERMANOVA test on β -diversity with 999 permutations considering even dependence
5 of samples (paired OCD samples after and before treatment). Finally, we applied a Principal Coordinate
6 Analysis (PCoA) to visualize the clustering of the samples.

7 **Statistical analysis**

8 Correlation between categorical variables (i.e. sample type, type of obsessions, etc.) and taxa
9 abundances or other continuous variables was tested using the Kruskal-Wallis rank sum test, and
10 correlation between two categorical variables was tested using Chi-squared tests. Statistical significance
11 of α -diversity differences between groups was evaluated with Mann-Whitney U test when samples
12 were independent, and with Wilcoxon rank-sum test when samples were paired. In all cases, we applied
13 the Bonferroni correction to adjust the p-values by the number of comparisons and provide only
14 corrected p-values. Correlation plots and boxplots were generated using *ggplot2* (version 2.2.1) and
15 association plots were generated using the *assoc* function from the R package *vcd* (version 1.4.4).
16 Linear discriminant analysis Effect Size (LEfSe) was performed using the Huttenhower lab's tool
17 implemented in Galaxy web (Segata et al., 2011). For the statistical test we used an α value of 0.05 and a
18 logarithmic LDA score threshold of 2.0.

19

20

21

22

23

24

1 RESULTS

2 High-throughput sequencing analysis of bacterial 16S rRNA V3–V4 regions was conducted on fecal and
3 oropharyngeal samples of the 32 OCD (two timepoints) and 33 control individuals (see Figure S1). In
4 total, 8,653,960 high-quality reads ($90,145.42 \pm 15,356.44$ reads/sample) were obtained from all 96 fecal
5 samples, representing 196 operational taxonomic units (OTUs) when considering all samples, while each
6 sample had, on average, 91.77 ± 17.51 OTUs. For the 96 oropharyngeal samples, 6,051,021 high-quality
7 reads ($63,031.47 \pm 16555$ reads/sample) were obtained, representing 81 operational taxonomic units for
8 all samples, with an average of 32.22 ± 9.29 OTUs/sample.

9 While statistical analyses revealed some differences between cases (at T0 and/or at T3) and controls, no
10 statistically significant differences were identified when comparing OCD cases before and after
11 treatment (T0 vs T3). On the other hand, we observed some association between some of the diet
12 variables and taxa abundances, but there were no significant associations between the variables
13 collected in the diet questionnaires and whether the individual belonged to the OCD or control group,
14 which suggests that the taxa differences between OCD cases and controls may be influenced by the OCD
15 phenotype, rather than by other variables.

16 **OCD samples show a trend towards lower bacterial α -diversity in the gut**

17 Analysis of the microbial composition of the gut showed that OCD T0 samples presented an overall
18 lower level of all α -diversity indices compared to the control group, although no test reached statistical
19 significance after adjusting for multiple testing (Bonferroni adjusted p-value = 0.057) (Figure 1A). These
20 differences were reduced in the OCD T3 group. On the other hand, we did not observe a strong
21 separation of sample groups based on the β -diversity measures (Figure S2), and there were no statistical
22 differences between the Bacteroidetes to Firmicutes ratio when comparing OCD samples to controls
23 (Wilcoxon rank-sum test Bonferroni adjusted p-value = 0.0653; Figure 2A). In all three groups, the 20

1 most abundant genera belonged to either the Bacteroidetes or Firmicutes Phyla, while at the family
2 level there was also representation of *Proteobacteria*, *Verrucomicrobia* and *Actinobacteria*, albeit at very
3 low abundances (Figure S3).

4 **LEfSe results reveal an enrichment for *Rikenellaceae* and depletion of *Prevotellaceae*, and a shift from** 5 ***Coprococcus* to *Flavonifractor* within the Clostridiales in the gut**

6 LEfSe analysis revealed a significant increase of the relative abundance of *Rikenellaceae*, particularly of
7 the *Alistipes* genus, and a decrease in the levels of *Prevotellaceae*, in OCD T0 stool samples compared to
8 controls (Figure 3). We also observed a different distribution of bacteria from the order Clostridiales,
9 where OCD T0 samples presented a higher abundance of the genera *Oscillibacter*, *Anaerostipes* and
10 *Flavonifractor*, and a depletion of *Agathobacter*, *Coprococcus*, *Lachnospira*, *Howardella*, *Romboutsia*,
11 *Butyricoccus* and *Clostridium* compared to controls. In addition, within these, depletion of *Lachnospira*
12 *pectinoschiza* correlated with OCD severity on the obsessions subscale (YBOCS_OBS_0 vs Species
13 *Lachnospira pectinoschiza* $r = -0.420$). Relative abundances in stool samples from cases and controls for
14 these taxa are presented in Table S5. Most of these differences are also present when comparing OCD
15 post-treatment samples versus controls (Figure S4).

16 **In the oropharyngeal microbiome, OCD samples show a lower Fusobacteria to Actinobacteria ratio**

17 Again, in the analysis of the oropharyngeal microbiome, α -diversity indices did not show significant
18 differences between the OCD and control groups (Figure 1B). Similarly, we did not see any separation of
19 sample groups based on most β -diversity measures (Figure S5). However, there was a significant
20 difference in the ratio of Fusobacteria to Actinobacteria when comparing OCD samples (T0 and T3) to
21 controls (Wilcoxon rank-sum test p-value = 0.004; c, Figure 2B), where OCD samples had lower ratios.
22 Bacterial diversity in the oropharyngeal samples was lower than in the stool samples (Shannon diversity:
23 Stool= 3.17 ± 0.46 , oropharyngeal= 2.46 ± 0.45 ; Faiths PD: Stool= 23.18 ± 4.00 , oropharyngeal= $15.25 \pm$

1 4.53). Among the 20 most abundant genera, the largest contribution belonged to the Actinobacteria and
2 Fusobacteria phyla, although Epsilonbacteraeota (e.g. *Campylobacter*), Bacteroidetes, Firmicutes and
3 Proteobacteria were also represented (Figure S6).

4
5 LEfSe analysis of the oropharyngeal microbiome data revealed an increase of species within the
6 Actinobacteria and Coriobacteriia classes in the OCD samples: particularly, the genera *Actinomyces* and
7 *Atopobium* represented a higher percentage of total bacteria in OCD T0 compared to control samples;
8 there was also an increase of *Lachnospiraceae* and other Firmicutes. In contrast, control samples had a
9 higher percentage of bacteria from the Fusobacteriia class (Figure 4). Analysis of OCD T3 vs controls
10 highlighted again the increase of the Actinobacteria and Coriobacteriia (Figure S7). Relative abundances
11 in oropharyngeal samples from cases and controls for these taxa are presented in Table S6.
12 We also performed a directed analysis of enrichment of *Streptococcus* in OCD samples versus controls,
13 as this genus has been shown to be associated to the onset of PANDAS (Quagliariello et al., 2018).
14 However, the top 15 most abundant species did not include bacteria from this genus in either OCD T0,
15 OCD T3, or controls.

17 DISCUSSION

18 We have performed an explorative comparative analysis of the gut (fecal) and oropharyngeal
19 microbiome between OCD cases (before and after treatment) and age- and gender-matched healthy
20 controls, via 16S rRNA amplicon sequencing.

21 While our analysis shows only a trend towards lower bacterial diversity in the gut of OCD patients which
22 is not significant after correction for multiple testing, this result is consistent with the lower gut α -
23 diversity in PANS/PANDAS patients reported by Quagliariello et al. (2018), and in OCD by Turna et al.
24 (2020). Lower α -diversity has also been reported in subjects with attention deficit hyperactivity disorder

1 (Prehn-Kristensen et al., 2018), and in some studies of ASD individuals (Kang et al., 2018; Kang et al.,
2 2013; Liu et al., 2019b), although it is not consistently observed, and may be dependent on the cohort
3 characteristics, including sample size. Nevertheless, most of these studies, as ours, are exploratory
4 analyses with small sample sizes, which may explain differences in the specific indexes reported
5 significant. In addition, in the analysis of Quagliariello et al. (2018) they also observed, in the younger
6 subset of PANS/PANDAS patients (aged 4-8 years), a higher percentage of Bacteroidetes and lower level
7 of Firmicutes, while we did not observe significant shifts in the Bacteroidetes to Firmicutes ratio. This
8 discrepancy between our results and those of Quagliariello et al. (2018) could be related to the age of
9 our subjects, as all our patients are adults, while their study was performed on pediatric cases. However,
10 we did not observe a correlation between age and any of the taxa ratios tested. Additional analyses on
11 larger cohorts should clarify the observed trends.

12 The Wilcoxon and LEfSe tests performed here highlighted differences in OTU abundances in the gut:
13 interestingly, we observed an increase of bacteria from the *Rikenellaceae* family, which had been
14 reported as a biomarker of PANDAS (Quagliariello et al., 2018). In addition, an increase in abundance of
15 *Rikenellaceae* has also been reported in ADHD (Aarts et al., 2017) and major depressive disorder (MDD)
16 (Jiang et al., 2015). This bacterial family and, specifically, the *Alistipes* genus, is also positively associated
17 with gut inflammation in human and mice studies (Bassett et al., 2015; Saulnier et al., 2011). Recently, a
18 study linked neuroinflammation throughout the CSTC circuit to OCD (Attwells et al., 2017). Considering
19 these observations, it is tempting to speculate a possible link between the neuroinflammation observed
20 in OCD patients and the higher abundance of *Alistipes* and *Rikenellaceae* in these patients. Finally, OCD
21 T0 samples showed lower levels of bacteria of the *Prevotellaceae* family, similarly to reports on ASD (Liu
22 et al., 2019b).

23 LEfSe analysis also found specific members of the Firmicutes phylum with higher abundance in OCD T0
24 samples: *Oscillibacter*, *Anaerostipes*, and *Flavonifractor*, and a lower abundance of *Coprococcus* and

1 *Lachnospira*; furthermore, abundance of *Lachnospira pectinoschiza* was also negatively correlated with
2 severity, in line with the depletion in cases compared to controls. While several of these differences are
3 maintained when comparing OCD post-treatment samples to the control group, the decrease in the
4 genus *Lachnospira* is not. Furthermore, Valles-Colomer et al. (2019) report a correlation of four mental
5 well-being scores (measured by the RAND-36 health-related quality of life survey) with higher
6 abundance of *Coprococcus*, and two of these (social functioning and emotional well-being) also correlate
7 with a lower abundance of *Flavonifractor* genus in the gut microbiota. We observe precisely the
8 opposite trend in our cohort of OCD patients, where OCD patients have lower abundance of
9 *Coprococcus* and higher abundance of *Flavonifractor*. The relative abundance of *Coprococcus* in the
10 aforementioned study was strongly associated with the microbial pathway for DOPAC (a dopamine
11 metabolite) synthesis. Relevantly, dopaminergic transmission has been implicated in the neurobiology of
12 OCD, as dopamine receptor agonists are effective as an augmentation therapy to selective serotonin
13 reuptake inhibitors in reducing OC symptoms (Vulink et al., 2009), and OCD patients under deep brain
14 stimulation show improvements associated with release of striatal dopamine (Figuee et al., 2014) .
15 However, our results are not replicating the findings by Turna et al. (2020). In their study, they observed
16 a lower relative abundance of *Oscillospira*, *Odoribacter* and *Anaerostipes*. We do not see a significant
17 difference for *Oscillospira* and *Odoribacter*, although a detailed look at the data show that, for
18 *Oscillospira*, a similar trend is present, with lower abundance in OCD T0 samples compared to controls,
19 and an increase in abundance in OCD T3 samples (supplementary table s5, figure S8). On the other hand,
20 in the case of *Anaerostipes* we observe an increase of these bacteria as opposed to what was previously
21 reported. These differences might be explained by chance, as both studies have a small, exploratory,
22 sample size, or it could be related to dietary differences or to methodological differences in the analysis
23 between both studies.
24 We also analyzed the oropharyngeal microbiome of OCD cases and controls. While the composition of

1 the oral microbiome has received little attention in relation with psychiatric diseases, there are some
2 studies that indicate possible changes in the oral microbiota of Parkinson's disease or autistic disorder
3 (Clarke et al., 1998; Hicks et al., 2018; Mihaila et al., 2019). In addition, the bacterial composition of the
4 oral cavity might be used to represent the composition of the upper gastrointestinal tract (Tsuda et al.,
5 2015). Furthermore, in this case we were particularly interested in the evaluation of the presence of
6 *Streptococcus pyogenes*, as a potential biomarker of OCD, as it had been associated with PANDAS
7 (Orefici et al., 2016), but we did not detect this species in our dataset. We then analyzed bacterial
8 diversity measures between cases and controls without observing an overall difference in α -diversity.
9 We did observe a significantly higher Actinobacteria to Fusobacteria ratio in OCD T0 compared to
10 controls, which is still present, but reduced, after treatment. This difference correlated with an increase
11 in *Actinomycetales* and a decrease of *Fusobacteriales* observed in the LEfSe analysis. We then analyzed
12 whether the Fusobacteria to Actinobacteria ratio could be used as a proxy for the increased abundance
13 of *Alistipes* and *Rikenellaceae* in the gut microbiome, but we did not detect a significant correlation with
14 either *Alistipes* or *Rikenellaceae*. The Fusobacteria/Actinobacteria ratio was, however, correlated with
15 the presence of the *Coprococcus* genus or the *Eggerthellaceae* family (Figure S9).

16

17 While our results support an imbalance in OCD cases, both in the gut and the oropharyngeal
18 microbiome, it is not possible to establish a causal relationship, as the observed changes in the
19 microbiome can be both a cause or a consequence of the disorder. It has been shown that the brain can
20 modulate the gut microbiome by a top-down function of the gut-brain axis. For instance, the lower α -
21 diversity observed in OCD cases could be a consequence of the anxiety provoked by obsessions. Since
22 our study included only patients already diagnosed with OCD, it is not possible to discern between cause
23 and effect. Further studies involving animal models, larger sample sizes, longitudinal cohorts and
24 eventually, interventional experiments, should help understand the contribution of intestinal and oral

1 microbiota to obsessive-compulsive disorder. In this regard, a recent animal study points toward the
2 existence of an underlying aetiological association between alterations in gut microbiota and
3 development of obsessive-compulsive behavior (Scheepers et al., 2019). Our analysis has some
4 limitations: the study sample size is relatively small, although in line with other exploratory studies in
5 autism or depression; on the other hand, gut microbiome composition has been analyzed through the
6 bacterial composition of stool samples, which represents mostly the composition of the colon, while
7 underestimating that of other regions of the gut such as the small intestine. Nevertheless, most
8 studies on the gut microbiome use this same sample source, as it is more accessible and less
9 invasive.

10 In summary, our results and those of others indicate that the gut microbiome might be playing a role in
11 the pathogenesis of OCD, which might involve an increase in inflammation levels related to
12 overabundance of bacteria in the *Alistipes* genus, or be related to a decrease in abundance of *Prevotella*
13 and *Coprococcus* genera, the latter associated with the microbial DOPAC synthesis pathway. While
14 awaiting confirmation on additional cohorts, these results open the door to further explorations into
15 possible interventions directed to the modulation of both the microbiota in OCD patients or the
16 mechanisms through which they exert their effect.

17
18
19
20
21
22
23
24

1 **ACKNOWLEDGEMENTS**

2

3 This project was supported by grants from the Spanish ministry of science and innovation (MICINN;
4 SAF2013-49108-R); the Carlos III Health Institute (PI16/00950 PI18/00856); FEDER funds ('A way to build
5 Europe') and by the Agency of University and Research Funding Management of the Catalan
6 Government (2014SGR1672). LD was supported by a Severo Ochoa grant (SVP-2013-068066), MA was
7 supported by the Secretariat for Universities and Research of the Ministry of Business and Knowledge of
8 the Government of Catalonia Grant co-funded by the European Social Fund (ESF) "ESF, Investing in your
9 future" (2017 FI_B 00327), DSC was supported by a grant from the MICINN (BES-2014-069814) and RR
10 was supported by a fellowship from the Health Department of the Generalitat de Catalunya through the
11 PERIS 2016-2020 program (SLT002/16/).

12

13

1 REFERENCES

- 2 Aarts, E., Ederveen, T.H.A., Naaijen, J., Zwiers, M.P., Boekhorst, J., Timmerman, H.M., Smeekens,
3 S.P., Netea, M.G., Buitelaar, J.K., Franke, B., van Hijum, S., Arias Vasquez, A., 2017. Gut microbiome in
4 ADHD and its relation to neural reward anticipation. *PLoS One* 12, e0183509.
- 5 Association, A.P., 1994. *DSM-IV-TR : Diagnostic and Statistical Manual of Mental Disorders*, 4th Ed.
6 American Psychiatric Press, Washington, DC.
- 7 Attwells, S., Setiawan, E., Wilson, A.A., Rusjan, P.M., Mizrahi, R., Miler, L., Xu, C., Richter, M.A., Kahn,
8 A., Kish, S.J., Houle, S., Ravindran, L., Meyer, J.H., 2017. Inflammation in the Neurocircuitry of Obsessive-
9 Compulsive Disorder. *JAMA Psychiatry* 74, 833-840.
- 10 Bailey, M.T., Dowd, S.E., Galley, J.D., Hufnagle, A.R., Allen, R.G., Lyte, M., 2011. Exposure to a social
11 stressor alters the structure of the intestinal microbiota: implications for stressor-induced
12 immunomodulation. *Brain Behav Immun* 25, 397-407.
- 13 Bassett, S.A., Young, W., Barnett, M.P., Cookson, A.L., McNabb, W.C., Roy, N.C., 2015. Changes in
14 composition of caecal microbiota associated with increased colon inflammation in interleukin-10 gene-
15 deficient mice inoculated with *Enterococcus* species. *Nutrients* 7, 1798-1816.
- 16 Bastiaanssen, T.F.S., Cowan, C.S.M., Claesson, M.J., Dinan, T.G., Cryan, J.F., 2019. Making Sense of ...
17 the Microbiome in Psychiatry. *Int J Neuropsychopharmacol* 22, 37-52.
- 18 Callahan, B.J., McMurdie, P.J., Rosen, M.J., Han, A.W., Johnson, A.J., Holmes, S.P., 2016. DADA2:
19 High-resolution sample inference from Illumina amplicon data. *Nat Methods* 13, 581-583.
- 20 Castro-Nallar, E., Bendall, M.L., Perez-Losada, M., Sabuncyan, S., Severance, E.G., Dickerson, F.B.,
21 Schroeder, J.R., Yolken, R.H., Crandall, K.A., 2015. Composition, taxonomy and functional diversity of the
22 oropharynx microbiome in individuals with schizophrenia and controls. *PeerJ* 3, e1140.

- 1 Clarke, R., Smith, A.D., Jobst, K.A., Refsum, H., Sutton, L., Ueland, P.M., 1998. Folate, vitamin B12,
2 and serum total homocysteine levels in confirmed Alzheimer disease. *Arch Neurol* 55, 1449-1455.
- 3 Cryan, J.F., Dinan, T.G., 2012. Mind-altering microorganisms: the impact of the gut microbiota on
4 brain and behaviour. *Nature Reviews Neuroscience* 13, 701.
- 5 Figeo, M., de Koning, P., Klaassen, S., Vulink, N., Mantione, M., van den Munckhof, P., Schuurman,
6 R., van Wingen, G., van Amelsvoort, T., Booij, J., Denys, D., 2014. Deep brain stimulation induces striatal
7 dopamine release in obsessive-compulsive disorder. *Biol Psychiatry* 75, 647-652.
- 8 First, M.B., Spitzer, R.L., Gibbon, M., Williams, J.B.W., 1996. Structured Clinical Interview for DSM-IV
9 Axis I Disorders-Clinician Version (SCID-CV). American Psychiatric Press, Washington, DC.
- 10 First, M.B., Spitzer, R.L., Gibbon, M., Williams, J.B.W., 2002. Structured Clinical Interview for DSM-IV-
11 TR Axis I Disorders, Research Version, Non-Patient Edition. (SCID-I/NP), New York: Biometrics Research.
12 New York State Psychiatric Institute.
- 13 Gasso, P., Ortiz, A.E., Mas, S., Morer, A., Calvo, A., Bargallo, N., Lafuente, A., Lazaro, L., 2015.
14 Association between genetic variants related to glutamatergic, dopaminergic and neurodevelopment
15 pathways and white matter microstructure in child and adolescent patients with obsessive-compulsive
16 disorder. *J Affect Disord* 186, 284-292.
- 17 Goodman, W.K., Price, L.H., Rasmussen, S.A., Mazure, C., Fleischmann, R.L., Hill, C.L., Heninger, G.R.,
18 Charney, D.S., 1989. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability.
19 *Arch Gen Psychiatry* 46, 1006-1011.
- 20 Hicks, S.D., Uhlig, R., Afshari, P., Williams, J., Chroneos, M., Tierney-Aves, C., Wagner, K., Middleton,
21 F.A., 2018. Oral microbiome activity in children with autism spectrum disorder. *Autism research : official*
22 *journal of the International Society for Autism Research* 11, 1286-1299.

- 1 Jiang, H., Ling, Z., Zhang, Y., Mao, H., Ma, Z., Yin, Y., Wang, W., Tang, W., Tan, Z., Shi, J., Li, L., Ruan,
2 B., 2015. Altered fecal microbiota composition in patients with major depressive disorder. *Brain Behav*
3 *Immun* 48, 186-194.
- 4 Kang, D.W., Ilhan, Z.E., Isern, N.G., Hoyt, D.W., Howsmon, D.P., Shaffer, M., Lozupone, C.A., Hahn, J.,
5 Adams, J.B., Krajmalnik-Brown, R., 2018. Differences in fecal microbial metabolites and microbiota of
6 children with autism spectrum disorders. *Anaerobe* 49, 121-131.
- 7 Kang, D.W., Park, J.G., Ilhan, Z.E., Wallstrom, G., Labaer, J., Adams, J.B., Krajmalnik-Brown, R., 2013.
8 Reduced incidence of *Prevotella* and other fermenters in intestinal microflora of autistic children. *PLoS*
9 *One* 8, e68322.
- 10 Klindworth, A., Pruesse, E., Schweer, T., Peplies, J., Quast, C., Horn, M., Glockner, F.O., 2013.
11 Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation
12 sequencing-based diversity studies. *Nucleic Acids Res* 41, e1.
- 13 Liu, F., Li, J., Wu, F., Zheng, H., Peng, Q., Zhou, H., 2019a. Altered composition and function of
14 intestinal microbiota in autism spectrum disorders: a systematic review. *Translational Psychiatry* 9, 43.
- 15 Liu, S., Li, E., Sun, Z., Fu, D., Duan, G., Jiang, M., Yu, Y., Mei, L., Yang, P., Tang, Y., Zheng, P., 2019b.
16 Altered gut microbiota and short chain fatty acids in Chinese children with autism spectrum disorder. *Sci*
17 *Rep* 9, 287.
- 18 Mattheisen, M., Samuels, J.F., Wang, Y., Greenberg, B.D., Fyer, A.J., McCracken, J.T., Geller, D.A.,
19 Murphy, D.L., Knowles, J.A., Grados, M.A., Riddle, M.A., Rasmussen, S.A., McLaughlin, N.C., Nurmi, E.L.,
20 Askland, K.D., Qin, H.D., Cullen, B.A., Piacentini, J., Pauls, D.L., Bienvenu, O.J., Stewart, S.E., Liang, K.Y.,
21 Goes, F.S., Maher, B., Pulver, A.E., Shugart, Y.Y., Valle, D., Lange, C., Nestadt, G., 2015. Genome-wide
22 association study in obsessive-compulsive disorder: results from the OCGAS. *Mol Psychiatry* 20, 337-344.

- 1 Mayer, E.A., Knight, R., Mazmanian, S.K., Cryan, J.F., Tillisch, K., 2014. Gut microbes and the brain:
2 paradigm shift in neuroscience. *J Neurosci* 34, 15490-15496.
- 3 Mihaila, D., Donegan, J., Barns, S., LaRocca, D., Du, Q., Zheng, D., Vidal, M., Neville, C., Uhlig, R.,
4 Middleton, F.A., 2019. The oral microbiome of early stage Parkinson's disease and its relationship with
5 functional measures of motor and non-motor function. *PLoS One* 14, e0218252.
- 6 Noh, H.J., Tang, R., Flannick, J., O'Dushlaine, C., Swofford, R., Howrigan, D., Genereux, D.P., Johnson,
7 J., van Grootheest, G., Grunblatt, E., Andersson, E., Djurfeldt, D.R., Patel, P.D., Koltookian, M., C, M.H.,
8 Pato, M.T., Pato, C.N., Rasmussen, S.A., Jenike, M.A., Hanna, G.L., Stewart, S.E., Knowles, J.A.,
9 Ruhrmann, S., Grabe, H.J., Wagner, M., Ruck, C., Mathews, C.A., Walitza, S., Cath, D.C., Feng, G.,
10 Karlsson, E.K., Lindblad-Toh, K., 2017. Integrating evolutionary and regulatory information with a
11 multispecies approach implicates genes and pathways in obsessive-compulsive disorder. *Nat Commun* 8,
12 774.
- 13 Orefici, G., Cardona, F., Cox, C.J., Cunningham, M.W., 2016. Pediatric autoimmune neuropsychiatric
14 disorders associated with streptococcal infections (PANDAS), in: J., F.J., L., S.D., A., F.V. (Eds.),
15 *Streptococcus pyogenes: Basic Biology to Clinical Manifestations*. University of Oklahoma Health
16 Sciences Center, Oklahoma city, OK.
- 17 Partrick, K.A., Chassaing, B., Beach, L.Q., McCann, K.E., Gewirtz, A.T., Huhman, K.L., 2018. Acute and
18 repeated exposure to social stress reduces gut microbiota diversity in Syrian hamsters. *Behav Brain Res*
19 345, 39-48.
- 20 Prehn-Kristensen, A., Zimmermann, A., Tittmann, L., Lieb, W., Schreiber, S., Baving, L., Fischer, A.,
21 2018. Reduced microbiome alpha diversity in young patients with ADHD. *PLoS One* 13, e0200728.

- 1 Qiao, Y., Wu, M., Feng, Y., Zhou, Z., Chen, L., Chen, F., 2018. Alterations of oral microbiota distinguish
2 children with autism spectrum disorders from healthy controls. *Sci Rep* 8, 1597.
- 3 Quagliariello, A., Del Chierico, F., Russo, A., Reddel, S., Conte, G., Lopetuso, L.R., Ianiro, G.,
4 Dallapiccola, B., Cardona, F., Gasbarrini, A., Putignani, L., 2018. Gut Microbiota Profiling and Gut-Brain
5 Crosstalk in Children Affected by Pediatric Acute-Onset Neuropsychiatric Syndrome and Pediatric
6 Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections. *Front Microbiol* 9,
7 675.
- 8 Rees, J.C., 2014. Obsessive-compulsive disorder and gut microbiota dysregulation. *Med Hypotheses*
9 82, 163-166.
- 10 Saulnier, D.M., Riehle, K., Mistretta, T.A., Diaz, M.A., Mandal, D., Raza, S., Weidler, E.M., Qin, X.,
11 Coarfa, C., Milosavljevic, A., Petrosino, J.F., Highlander, S., Gibbs, R., Lynch, S.V., Shulman, R.J.,
12 Versalovic, J., 2011. Gastrointestinal microbiome signatures of pediatric patients with irritable bowel
13 syndrome. *Gastroenterology* 141, 1782-1791.
- 14 Scheepers, I.M., Cryan, J.F., Bastiaanssen, T.F.S., Rea, K., Clarke, G., Jaspán, H.B., Harvey, B.H.,
15 Hemmings, S.M.J., Santana, L., van der Sluis, R., Malan-Muller, S., Wolmarans, W., 2019. Natural
16 compulsive-like behaviour in the deer mouse (*Peromyscus maniculatus bairdii*) is associated with altered
17 gut microbiota composition. *Eur J Neurosci*.
- 18 Schwarz, E., Maukonen, J., Hyytiäinen, T., Kieseppa, T., Oresic, M., Sabunciyan, S., Mantere, O.,
19 Saarela, M., Yolken, R., Suvisaari, J., 2018. Analysis of microbiota in first episode psychosis identifies
20 preliminary associations with symptom severity and treatment response. *Schizophr Res* 192, 398-403.
- 21 Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W.S., Huttenhower, C., 2011.
22 Metagenomic biomarker discovery and explanation. *Genome Biol* 12, R60.

- 1 Servaes, S., Glorie, D., Verhaeghe, J., Stroobants, S., Staelens, S., 2017. Preclinical molecular imaging
2 of glutamatergic and dopaminergic neuroreceptor kinetics in obsessive compulsive disorder. *Prog*
3 *Neuropsychopharmacol Biol Psychiatry* 77, 90-98.
- 4 Snider, L.A., Swedo, S.E., 2004. PANDAS: current status and directions for research. *Mol Psychiatry* 9,
5 900-907.
- 6 Stewart, S.E., Yu, D., Scharf, J.M., Neale, B.M., Fagerness, J.A., Mathews, C.A., Arnold, P.D., Evans,
7 P.D., Gamazon, E.R., Davis, L.K., Osiecki, L., McGrath, L., Haddad, S., Crane, J., Hezel, D., Illman, C.,
8 Mayerfeld, C., Konkashbaev, A., Liu, C., Pluzhnikov, A., Tikhomirov, A., Edlund, C.K., Rauch, S.L.,
9 Moessner, R., Falkai, P., Maier, W., Ruhrmann, S., Grabe, H.J., Lennertz, L., Wagner, M., Bellodi, L.,
10 Cavallini, M.C., Richter, M.A., Cook, E.H., Jr., Kennedy, J.L., Rosenberg, D., Stein, D.J., Hemmings, S.M.,
11 Lochner, C., Azzam, A., Chavira, D.A., Fournier, E., Garrido, H., Sheppard, B., Umana, P., Murphy, D.L.,
12 Wendland, J.R., Veenstra-VanderWeele, J., Denys, D., Blom, R., Deforce, D., Van Nieuwerburgh, F.,
13 Westenberg, H.G., Walitza, S., Egberts, K., Renner, T., Miguel, E.C., Cappi, C., Hounie, A.G., Conceicao do
14 Rosario, M., Sampaio, A.S., Vallada, H., Nicolini, H., Lanzagorta, N., Camarena, B., Delorme, R., Leboyer,
15 M., Pato, C.N., Pato, M.T., Voyiaziakis, E., Heutink, P., Cath, D.C., Posthuma, D., Smit, J.H., Samuels, J.,
16 Bienvenu, O.J., Cullen, B., Fyer, A.J., Grados, M.A., Greenberg, B.D., McCracken, J.T., Riddle, M.A., Wang,
17 Y., Coric, V., Leckman, J.F., Bloch, M., Pittenger, C., Eapen, V., Black, D.W., Ophoff, R.A., Strengman, E.,
18 Cusi, D., Turiel, M., Frau, F., Macciardi, F., Gibbs, J.R., Cookson, M.R., Singleton, A., North American Brain
19 Expression, C., Hardy, J., Database, U.K.B.E., Crenshaw, A.T., Parkin, M.A., Mirel, D.B., Conti, D.V.,
20 Purcell, S., Nestadt, G., Hanna, G.L., Jenike, M.A., Knowles, J.A., Cox, N., Pauls, D.L., 2013. Genome-wide
21 association study of obsessive-compulsive disorder. *Mol Psychiatry* 18, 788-798.
- 22 Tomova, A., Husarova, V., Lakatosova, S., Bakos, J., Vlkova, B., Babinska, K., Ostatnikova, D., 2015.
23 Gastrointestinal microbiota in children with autism in Slovakia. *Physiol Behav* 138, 179-187.

- 1 Tsuda, A., Suda, W., Morita, H., Takanashi, K., Takagi, A., Koga, Y., Hattori, M., 2015. Influence of
2 Proton-Pump Inhibitors on the Luminal Microbiota in the Gastrointestinal Tract. *Clin Transl*
3 *Gastroenterol* 6, e89.
- 4 Turna, J., Grosman Kaplan, K., Anglin, R., Patterson, B., Soreni, N., Bercik, P., Surette, M.G., Van
5 Ameringen, M., 2020. The gut microbiome and inflammation in Obsessive-Compulsive Disorder patients
6 compared to age- and sex-matched controls: a pilot study. *Acta Psychiatr Scand*.
- 7 Turna, J., Grosman Kaplan, K., Anglin, R., Van Ameringen, M., 2016. "What's Bugging the Gut in
8 Ocd?" a Review of the Gut Microbiome in Obsessive-Compulsive Disorder. *Depress Anxiety* 33, 171-178.
- 9 Valles-Colomer, M., Falony, G., Darzi, Y., Tigchelaar, E.F., Wang, J., Tito, R.Y., Schiweck, C.,
10 Kurilshikov, A., Joossens, M., Wijmenga, C., Claes, S., Van Oudenhove, L., Zhernakova, A., Vieira-Silva, S.,
11 Raes, J., 2019. The neuroactive potential of the human gut microbiota in quality of life and depression.
12 *Nat Microbiol*.
- 13 Vulink, N.C., Denys, D., Fluitman, S.B., Meinardi, J.C., Westenberg, H.G., 2009. Quetiapine augments
14 the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind,
15 placebo-controlled study of 76 patients. *J Clin Psychiatry* 70, 1001-1008.
- 16 Vuong, H.E., Hsiao, E.Y., 2017. Emerging Roles for the Gut Microbiome in Autism Spectrum Disorder.
17 *Biol Psychiatry* 81, 411-423.
- 18 Yilmaz, P., Parfrey, L.W., Yarza, P., Gerken, J., Pruesse, E., Quast, C., Schweer, T., Peplies, J., Ludwig,
19 W., Glockner, F.O., 2014. The SILVA and "All-species Living Tree Project (LTP)" taxonomic frameworks.
20 *Nucleic Acids Res* 42, D643-648.
- 21
- 22

1 **TABLES**

2 **Table 1.** Age and gender characteristics for the control and OCD sample cohorts.

3

Group	Female	Male	Age	Diet					
			Aver (SD; range)	Q6	Q7	Q11	Q12	Q17	Q18
OCD	20	18	40.16 (14.12;18-71)	1.5	2.4	3.1	2.2	2.1	2.5
Control	18	15	36.00 (9.87; 23-59)	2.15	2.4	3.6	2.1	2.1	2.5

4

5 Female/Male: number of female/male participants; Aver: average; SD: standard deviation; Diet: average
6 value for group responses to questionnaire questions Q6 (alcohol); Q7 (yoghurt, kefir...); Q11
7 (vegetables); Q12 (beans); Q17 (red meat) and Q18 (white meat); values range from 1 (not in last 7 days)
8 to 4 (daily). For more details, see questionnaire in supplementary table S3.

9

10

11

12

13

14

15

16 **FIGURES**

17 **Figure 1.** Boxplots representing α -diversity indices: Observed, Chao1, ACE, Shannon, Simpson, Inverted
18 Simpson, Fisher and PD. The plots represent the median, 25th, and 75th percentiles calculated for
19 Controls (red), OCD T0 (green) and OCD T3 (blue) in stool samples (a) or oropharyngeal samples (b). The
20 corresponding Bonferroni adjusted p-values are reported below each index (OCD T0 vs controls and OCD
21 T3 vs controls was calculated with Mann–Whitney U test; OCD T0 vs OCD T3 with Wilcoxon rank-sum
22 test).



A**B**

Figure 2. Notched boxplots representing the values of the ratio for the two most abundant taxa in

each area: **a.** Firmicutes to Bacteroidetes ratio in gut samples from Control, OCD T0 and OCD T3

subjects. **b.** Fusobacteria to Actinobacteria ratio in Oropharyngeal samples from Control, OCD T0 and

OCD T3 subjects. Bonferroni adjusted p-value of Wilcoxon rank-sum test between Controls and OCD

T0, and controls and OCD T3 are indicated.



A**B**

Figure 3.a. Biomarkers associated with OCD and control groups discovered by LEfSe analysis (α

value=0.05, logarithmic LDA score threshold=2.0) in stool samples. **b.** Cladogram representing the

phylogenetic relationship of biomarkers associated with OCD and control groups through the Linear

discriminant Effect Size (LEfSe) analysis (α value=0.05, logarithmic LDA score threshold=2.0) in stool

samples.



A**B**

Figure 4. a. Biomarkers associated with OCD and control groups discovered by LEfSe analysis (α

value=0.05, logarithmic LDA score threshold=2.0) in oropharyngeal samples. **b.** Cladogram

representing the phylogenetic relationship of biomarkers associated with OCD and control groups

through the Linear discriminant Effect Size (LEfSe) analysis (α value=0.05, logarithmic LDA score

threshold=2.0) in oropharyngeal samples.

